The need to define treatment goals for systemic lupus erythematosus

Nature Reviews Rheumatology

Volumn 10, Issue 9, 2014, Pages 567-571

  Franklyn, Kate ^a   Hoi, Alberta ^a   Nikpour, Mandana ^b   Morand, Eric F ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CONSENSUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE MARKER; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG RESEARCH; EVIDENCE BASED MEDICINE; HEALTH CARE NEED; HUMAN; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT INDICATION; TREATMENT RESPONSE; BIOASSAY; TREATMENT OUTCOME;

ENDPOINT DETERMINATION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; TREATMENT OUTCOME;

EID: 84908099269     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2014.118     Document Type: Review

References (40)

1. Uramoto, K. M. et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992. Arthritis Rheum. 42, 46-50 (1999).
2. Mak, A., Cheung, M. W., Chiew, H. J., Liu, Y. & Ho, R. C. Global trend of survival and damage of systemic lupus erythematosus: Meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin. Arthritis Rheum. 41, 830-839 (2012).
3. Cook, C. D., Wedgewood, R. J., Craig, J. M., Hartmann, J. R. & Janeway, C. A. Systemic lupus erythematosus. Description of 37 cases in children and a discussion of endocrine therapy in 32 of the cases. Pediatrics 26, 570-585 (1960).
4. van Vollenhoven, R. F. et al. Treat-to-target in systemic lupus erythematosus: Recommendations from an international task force. Ann. Rheum. Dis. 73, 958-967(2014).
5. Verdecchia, P. et al. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): An open-label randomised trial. Lancet 374, 525-533 (2009).
6. Grigor, C. et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): A single-blind randomised controlled trial. Lancet 364, 263-269 (2004).
7. Verstappen, S. M. et al. Intensive treatment with methotrexate in early rheumatoid arthritis: Aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann. Rheum. Dis. 66, 1443-1449 (2007).
8. Bernatsky, S. et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 54, 2550-2557 (2006).
9. Mok, C. C., To, C. H., Ho, L. Y. & Yu, K. L. Incidence and mortality of systemic lupus erythematosus in a southern Chinese population, 2000-2006. J. Rheumatol. 35, 1978-1982 (2008).
10. Urowitz, M. B., Gladman, D. D., Tom, B. D., Ibañez, D. & Farewell, V. T. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J. Rheumatol. 35, 2152-2158 (2008).
11. Manzi, S. et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am. J. Epidemiol. 145, 408-415 (1997).
12. Nived, O., Jönsen, A., Bengtsson, A. A., Bengtsson, C. & Sturfelt, G. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus. J. Rheumatol. 29, 1398-1400 (2002).
13. Nossent, J. et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 19, 949-956 (2010).
14. Uribe, A. G., McGwin, G., Jr, Reveille, J. D. & Alarcón, G. S. What have we learned from a 10-year experience with the LUMINA (Lupus in Minorities; Nature vs. nurture) cohort? Where are we heading? Autoimmun. Rev. 3, 321-329 (2004).
15. Alarcón, G. S. et al. Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. Rheumatology (Oxford) 43, 202-205 (2004).
16. Da Silva, J. A. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: Published evidence and prospective trial data. Ann. Rheum. Dis. 65, 285-293 (2006).
17. Ibañez, D., Gladman, D. D. & Urowitz, M. B. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J. Rheumatol. 32, 824-827 (2005).
18. Nikpour, M., Urowitz, M. B., Ibañez, D., Harvey, P. J. & Gladman, D. D. Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: A prospective proofofconcept cohort study. Arthritis Res. Ther. 13, R156 (2011).
19. Golder, V., Connelly, K., Staples, M., Morand, E. & Hoi, A. Association of Asian ethnicity with disease activity in SLE: An observational study from the Monash Lupus Clinic. Lupus 22, 1425-1430 (2013).
20. Turchetti, G., Yazdany, J., Palla, I., Yelin, E. & Mosca, M. Systemic lupus erythematosus and the economic perspective: A systematic literature review and points to consider. Clin. Exp. Rheumatol. 30 (4 Suppl. 73) S116-S122 (2012).
21. Sutcliffe, N., Clarke, A. E., Taylor, R., Frost, C. & Isenberg, D. A. Total costs and predictors of costs in patients with systemic lupus erythematosus. Rheumatology (Oxford) 40, 37-47 (2001).
22. Gladman, D. et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 39, 363-369 (1996).
23. Bombardier, C., Gladman, D. D., Urowitz, M. B., Caron, D. & Chang, C. H. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum. 35, 630-640 (1992).
24. Strand, V. Clinical trial design in systemic lupus erythematosus: Lessons learned and future directions. Lupus 13, 406-411 (2004).
25. Yee, C.S. et al. Revised British Isles Lupus Assessment Group 2004 index: A reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum. 54, 3300-3305 (2006).
26. Neville, C. et al. Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity. J. Rheumatol. 27, 675-679 (2000).
27. Yen, J. C. et al. Determinants of discordance between patients and physicians in their assessment of lupus disease activity. J. Rheumatol. 30, 1967-1976 (2003).
28. Wallace, D. J. et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 61, 1168-1178 (2009).
29. Wallace, D. J. et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: Results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann. Rheum. Dis. 73, 183-190 (2013).
30. Urowitz, M. B., Feletar, M., Bruce, I. N., Ibañez, D. & Gladman, D. D. Prolonged remission in systemic lupus erythematosus. J. Rheumatol. 32, 1467-1472 (2005).
31. Steiman, A. J., Gladman, D. D., Ibañez, D. & Urowitz, M. B. Prolonged serologically active clinically quiescent systemic lupus erythematosus: Frequency and outcome. J. Rheumatol. 37, 1822-1827 (2010).
32. Steiman, A. J., Gladman, D. D., Ibañez, D. & Urowitz, M. B. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. Arthritis Care Res. 64, 511-518 (2012).
33. Khanna, D. et al. Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. Arthritis Rheum. 57, 440-447 (2007).
34. Rullo, O. J. & Tsao, B. P. Recent insights into the genetic basis of systemic lupus erythematosus. Ann. Rheum. Dis. 72 (Suppl. 2), ii56-ii61 (2013).
35. Alarcón, G. S. et al. Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum. 45, 191-202 (2001).
36. Walsh, S. J. & DeChello, L. M. Geographical variation in mortality from systemic lupus erythematosus in the United States. Lupus 10, 637-646 (2001).
37. Bossingham, D. Systemic lupus erythematosus in the far north of Queensland. Lupus 12, 327-331 (2003).
38. Gladman, D. D., Ibañez, D. & Urowitz, M. B. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 29, 288-291 (2002).
39. van der Heijde, D. M., van 't Hof, M., van Riel, P. L. & van de Putte, L. B. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J. Rheumatol. 20, 579-581 (1993).
40. Felson, D. T. et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 63, 573-586 (2011).